Clinical research
Galmed announces positive late-stage results in biopsy-proven NASH patients.
Geron announced Wednesday positive topline results from the Phase III IMerge trial evaluating the telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes patients.
Vera Therapeutics’ stock crashed following the reveal of data from a Phase IIb study of atacicept in IgAN.
Amgen’s Repatha may cause cardiac harm, according to a reassessment of the biologic’s late-stage trial data.
Chemomab’s experimental antibody shows promise in NASH.
Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
Lexicon Pharmaceuticals’ LX9211 fell short of its primary efficacy endpoint, according to topline data from the Phase II RELIEF-PHN-1 study in post-herpetic neuralgia.
Jazz Pharmaceuticals exercised its option on Zymeworks’ promising anti-cancer agent.
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
PRESS RELEASES